LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $90.80, for a total value of $136,200.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Daniel Jeffrey Moore also recently made the following trade(s):
- On Saturday, December 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $91.85, for a total value of $91,850.00.
- On Thursday, November 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $116.68, for a total value of $116,680.00.
NASDAQ LIVN opened at $92.32 on Friday. The company has a market cap of $4.49 billion, a PE ratio of 28.85, a P/E/G ratio of 2.68 and a beta of 0.91. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65. LivaNova PLC has a fifty-two week low of $79.96 and a fifty-two week high of $131.54.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.08). The company had revenue of $272.10 million for the quarter, compared to the consensus estimate of $275.03 million. LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.83 EPS. On average, equities analysts expect that LivaNova PLC will post 3.09 earnings per share for the current year.
Several analysts have recently issued reports on the company. BidaskClub raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 8th. Jefferies Financial Group boosted their target price on LivaNova to $150.00 and gave the company a “buy” rating in a research report on Tuesday, October 2nd. BTIG Research reissued a “hold” rating on shares of LivaNova in a research report on Thursday, November 1st. UBS Group began coverage on LivaNova in a research report on Tuesday, November 27th. They set a “neutral” rating and a $105.00 target price on the stock. Finally, ValuEngine downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 28th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $122.20.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd bought a new position in LivaNova in the 3rd quarter valued at $108,000. Bamco Inc. NY bought a new position in LivaNova in the 3rd quarter valued at $143,000. Gilder Gagnon Howe & Co. LLC bought a new position in LivaNova in the 3rd quarter valued at $167,000. Cerebellum GP LLC bought a new position in LivaNova in the 3rd quarter valued at $191,000. Finally, Meeder Asset Management Inc. grew its position in LivaNova by 130.8% in the 4th quarter. Meeder Asset Management Inc. now owns 1,632 shares of the company’s stock valued at $148,000 after acquiring an additional 925 shares during the last quarter. 86.89% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2019/01/20/insider-selling-livanova-plc-livn-director-sells-136200-00-in-stock.html.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
See Also: Is a Roth IRA right for you?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.